Osteoporosis and lung transplantation: a prospective study.

STUDY OBJECTIVE Osteoporosis is a well-recognized complication of lung transplantation that may significantly impair the quality of life of transplant recipients. We performed a prospective study of bone mineral density (BMD) before and after transplantation to determine the degree of bone mass loss associated with lung transplantation Patients and design: We conducted a prospective study of BMD in 28 patients with various end-stage respiratory diseases pretransplantation and 6 to 12 months posttransplantation. The BMD of the lumbar spine (LS) and femoral neck (FN) were measured. All 28 patients were treated only with vitamin D and calcium supplementation posttransplant. The primary endpoint was the percentage change in BMD. The secondary endpoint was the incidence of fractures posttransplant. A univariate analysis was conducted to determine the various risk factors associated with bone mass loss pretransplant and posttransplant. RESULTS Prior to transplantation, moderate to severe bone disease was evident. The mean (+/- SD) pretransplant T score (the number of SDs from the peak bone mass) and Z score (the number of SDs from the age-matched mean) for the LS were -1.72 +/- 1.37 and -1.44 +/- 1.31, respectively. The mean pretransplant T score and Z score for the FN were -2.65 +/- 1.01 and -1.5 +/- 1.43, respectively. Within 6 to 12 months posttransplant, the mean BMD for the LS decreased by 4.76% (p < 0.001), while the mean BMD for the FN decreased by 5.3% (p < 0.001). Five of the 28 patients (18%) suffered osteoporotic fractures posttransplant, while no fractures were documented pretransplant. The cumulative steroid dose posttransplant was associated with a drop in BMD for the LS and FN (r = 0.39, p = 0.039 and r = 0.63, p < 0.001, respectively), while a negative association was found between cumulative steroid use pretransplant and baseline LS and FN T scores (r = -0.4, p = 0. 02 and r = -0.43, p = 0.023, respectively). CONCLUSION Within 6 to 12 months after lung transplantation, there is a significant decrease in BMD at both the LS and FN levels (approximately 5%) despite vitamin D and calcium supplementation. This drop in BMD is associated with a relatively high incidence of osteoporotic fractures posttransplant.

[1]  S. Ikuyama,et al.  Glucocorticoid-induced osteoporosis: pathogenesis and management , 2000, Journal of Bone and Mineral Metabolism.

[2]  Jacques P. Brown,et al.  Alendronate for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis , 1998 .

[3]  Jacques P. Brown,et al.  Intermittent etidronate therapy to prevent corticosteroid-induced osteoporosis. , 1997, The New England journal of medicine.

[4]  R. Rizzoli,et al.  Osteoporosis in patients undergoing lung transplantation. , 1996, The European respiratory journal.

[5]  E. Shane,et al.  Osteoporosis in lung transplantation candidates with end-stage pulmonary disease. , 1996, The American journal of medicine.

[6]  J. Myers,et al.  Long-term Health Status and Quality of Life Outcomes of Lung Transplant Recipients , 1996 .

[7]  T. Egan,et al.  Severe osteoporosis before and after lung transplantation. , 1996, Chest.

[8]  J. Bilezikian,et al.  Organ transplantation and osteoporosis. , 1995, Current opinion in rheumatology.

[9]  P. Delmas,et al.  Bone loss after orthotopic liver transplantation. , 1994, The American journal of medicine.

[10]  L. Larrodera,et al.  Bone loss and turnover in patients with liver transplantation. , 1994, Hepato-gastroenterology.

[11]  J. Casez,et al.  Changes in bone mass early after kidney transplantation , 1994, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[12]  J. Eisman,et al.  Bone loss after heart transplantation: a prospective study. , 1994, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[13]  B. Riggs,et al.  Glucocorticoid regulation of insulin-like growth factor-binding protein expression in normal human osteoblast-like cells. , 1994, Endocrinology.

[14]  J. Cunningham,et al.  Loss of regional bone mineral density in the first 12 months following renal transplantation. , 1994, Nephron.

[15]  I. Reid,et al.  Bone mineral density and body composition in adult patients with cystic fibrosis. , 1993, Thorax.

[16]  E. Shane,et al.  Osteoporosis after cardiac transplantation. , 1993, The American journal of medicine.

[17]  F. Hawkins,et al.  Effect of liver transplantation and immunosuppressive treatment on bone mineral density. , 1992, Transplantation proceedings.

[18]  S. Epstein,et al.  Perspectives: Posttransplantation bone disease , 1992 .

[19]  G. McCaughan,et al.  Bone loss after liver transplantation , 1991, Hepatology.

[20]  B. Julian,et al.  Rapid loss of vertebral mineral density after renal transplantation. , 1991, The New England journal of medicine.

[21]  E. Dickson,et al.  Rates of vertebral bone loss before and after liver transplantation in women with primary biliary cirrhosis , 1991, Hepatology.

[22]  T. Strom,et al.  Abrogation of glucocorticoid-mediated inhibition of T cell proliferation by the synergistic action of IL-1, IL-6, and IFN-gamma. , 1991, Journal of immunology.

[23]  E. Dickson,et al.  Bone disease in liver transplant recipients: incidence, timing, and risk factors. , 1991, Transplantation proceedings.

[24]  M. Prummel,et al.  The course of biochemical parameters of bone turnover during treatment with corticosteroids. , 1991, The Journal of clinical endocrinology and metabolism.

[25]  Y. Ye,et al.  Loss of vertebral bone density in heart transplant patients. , 1991, Transplantation proceedings.

[26]  L. Raisz,et al.  Glucocorticoid-induced osteoporosis: pathogenesis and management. , 1990, Annals of internal medicine.

[27]  I. Reid,et al.  Prevention of steroid-induced osteoporosis with (3-amino-1-hydroxypropylidene)-1,1-bisphosphonate (APD) , 1988 .

[28]  D. Fink,et al.  SCREENING FOR BREAST CANCER , 1976, The Lancet.